p53: Guardian of cellular senescence

Journal of Pathology

Volumn 180, Issue 2, 1996, Pages 118-121

  Wynford Thomas, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

CELL AGING; CHROMOSOME ABERRATIONS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029801598     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I     Document Type: Review

References (40)

1. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995; 11: 36-140.
2. Powell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995; 177: 221-224.
3. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
4. Blondal JA, Benchimol S. The role of p53 in tumour progression. Semin Cancer Biol 1994; 5: 177-186.
5. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-141.
6. Wynford-Thomas D. Molecular-genetics of thyroid cancer. Trends Endocrinol Metab 1993; 4: 224-243.
7. Sidransky D, Millelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-847.
8. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991; 87: 2042-2047.
9. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
10. Baker SJ, Morkovitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-915.
11. El-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-2919.
12. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
13. Lane DP. p53, guardian of the genome Nature 1992; 358: 15-16.
14. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. BioEssays 1995; 17: 501-508.
15. Shackney SE, Smith CA, Miller BW, et al. Model for genetic evolution of human solid tumours. Cancer Res 1989; 49: 3344-3354.
16. Livingstone LR, White A. Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935.
17. Nishino H, Knoll A, Buettner VL, et al. p53 wild-type and p53 nullizygous Big Blue transgenic mice have similar frequencies and patterns of observed mutation in liver, spleen and brain. Oncogene 1995; 11: 263-270.
18. Sands AT, Suraokar MB, Sanchez A, Marth JE, Donehower LA, Bradley A. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc Natl Acad Sci USA 1995; 92: 8517-8521.
19. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-777.
20. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
21. Bacchetti S, Counter CM. Telomeres and telomerase in human cancer. Int J Oncol 1995; 7; 423-432.
22. Vojta PJ, Carl Barrett J. Genetic analysis of cellular senescence. Biochim Biophys Acta 1995; 1242: 29-41.
23. Edington KG, Loughran OP, Berry IJ, Parkinson EK. Cellular immortality: a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol Carcinogen 1995; 13: 254-265.
24. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196: 33-39.
25. Hara E, Tsurui H, Shinozaki A, Nakada S, Oda K. Co-operative effect of antisense-Rb and antisense-p53 oligomers on the extension of the lifespan in human diploid fibroblasts, TIG-1. Biochem Biophys Res Commun 1991; 179: 528-534.
26. Bond JA, Wyllie FS, Wynford-Thomas D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 1994; 9: 1885-1889.
27. Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford-Thomas D. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SD11/WAF1. Cancer Res 1995; 55: 2404-2409.
28. Rogan EM, Bryan TM, Hukku B, et al. Alterations in p53 and p16ink4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995; 15: 4745-4753.
29. Bond JA, Haughton M, Blaydes JP, Wynford-Thomas D, Wyllie FS. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. (Submitted).
30. Shay JW, Tomlinson G, Piatyszek MA, Gollahon LS. Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol 1995; 15: 425-432.
31. Reznikoff CA, Belair C, Savelieva E. et al. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev 1994; 8: 2227-2240.
32. Wynford-Thomas D, Jones CJ, Wyllie FS. The tumour suppressor gene p53 as a regulator of proliferative lifespan and tumour progression. Biological Signals 1996; 5: 139-153.
33. Wyllie F, Lemoine N, Barton C, Dawson T, Bond J, Wynford-Thomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogen 1993; 7: 83-88.
34. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5: 293-297.
35. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-460.
36. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Nail Acad Sci USA 1992; 89: 10114-10118.
37. Benn PA. Specific chromosome aberrations in senescent fibroblast cell lines derived from human embryos. Am J Human Genet 1976; 28: 465-473.
38. Wynford-Thomas D. Does telomere shortening drive selection for p53 mutation in human cancer? Mol Carcinogen 1995; 12: 119-123.
39. Enoch T, Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. TIBS 1995; 20: 426-430.
40. Hann BC, Lane DP. The dominating effect of mutant p53. Nature Genet 1995; 9: 221-223.